(Reuters) – Eli Lilly and Company said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderately to severely active ulcerative colitis, a type of chronic inflammatory bowel disease.
(Reporting by Pratik Jain in Benagluru; Editing by Anil D’Silva)
